Atara Biotherapeutics Gains FDA Alignment on Tab-cel BLA Resubmission Path for EBV+ PTLD

A precedent-setting concession from FDA on study design adequacy is now shaping how Atara Biotherapeutics and partner Pierre Fabre Pharmaceuticals (PFP) will structure the resubmission of the tabelecleucel (tab-cel) Biologics License Application (BLA) for relapsed/refractory EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Following a Type A meeting convened to address the Complete Response Letter (CRL) previously issued against the tab-cel BLA, FDA confirmed that a single-arm study using a pre-specified, appropriate historical control can constitute an adequate and well-controlled study for this indication. For regulatory affairs and CMC teams working in rare oncology cell therapy, that alignment carries direct implications for how pivotal evidence packages are assembled and defended under 21 CFR Part 314 and biologics review standards.

PFP has indicated it will submit an updated dataset incorporating additional patients and extended follow-up from the pivotal Phase 3 ALLELE study, which enrolled adults and pediatric patients aged two years and older with R/R EBV+ PTLD following solid organ transplant or hematopoietic cell transplant. Supportive data will accompany the primary dataset as part of a resubmission plan being defined collaboratively with the agency.

For QA directors and manufacturing leads, the cell therapy context adds a layer of complexity absent from conventional biologics resubmissions. Allogeneic T-cell products carry sterility assurance, release testing, and comparability obligations that must remain consistent across the expanded patient dataset. Any manufacturing changes introduced since the original BLA filing will require documented bridging under ICH Q10 quality system principles and may draw scrutiny during the resubmission review cycle.

Atara has indicated a further regulatory update is expected in Q3 2026, which will likely define the formal resubmission timeline and clarify whether any CMC supplements accompany the clinical data package.

Source: Atara Biotherapeutics via Business Wire, 7 May 2026.